New hope for Hard-to-Treat cancers: experimental drug enters human trials

NCT ID NCT04900818

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests an experimental drug called TJ033721 (givastomig) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. About 330 participants will receive the drug alone or in combination with other therapies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenocarcinoma Of Esophagus biliary tract cancer Biliary Tract Neoplasms cancer esophageal adenocarcinoma gastric cancer gastric neoplasm gastroesophageal junction adenocarcinoma metastatic malignant neoplasm Neoplasm Metastasis pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing Cancer Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100142, China

  • Carolina BioOncology Institute

    COMPLETED

    Huntersville, North Carolina, 28078, United States

  • HARBIN Medical University Cancer Hospital

    COMPLETED

    Harbin, Heilongjiang, 150086, China

  • Henan Cancer Hospital

    COMPLETED

    Zhengzhou, Henan, 45003, China

  • Horizon Oncology Research, LLC.

    COMPLETED

    Layfayette, Indiana, 47905, United States

  • Hubei Cancer Hospital

    COMPLETED

    Wuhan, Hubei, 430079, China

  • Mary Crowley Cancer Research

    COMPLETED

    Dallas, Texas, 75230, United States

  • Mass General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10065, United States

  • NYU Langone

    RECRUITING

    New York, New York, 10016, United States

  • Rutgers Cancer Institute of New Jersey

    COMPLETED

    New Brunswick, New Jersey, 08901, United States

  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

    COMPLETED

    Hangzhou, Zhejiang, 3110020, China

  • Sixth Affiliated Hospital, Sun Yat-sen University

    ACTIVE_NOT_RECRUITING

    Guangzhou, Guangdong, 510655, China

  • Stern Center for Cancer Clinical Trials and Research

    RECRUITING

    Orange, California, 92868, United States

  • The First Hospital of China Medical University

    COMPLETED

    Shenyang, Liaoning, 110499, China

  • The Second Hospital of Anhui Medical University

    WITHDRAWN

    Hefei, Anhui, 230601, China

  • Tianjin Medical University Cancer Institute and Hospital

    COMPLETED

    Tianjin, Tianjin Municipality, 300060, China

  • UCHealth Cancer Care - Anschutz Medical Campus

    RECRUITING

    Aurora, Colorado, 80045, United States

  • UW Carbone Cancer Center

    RECRUITING

    Madison, Wisconsin, 53705, United States

  • Vanderbilt-Ingram Cancer Center

    COMPLETED

    Nashville, Tennessee, 37232, United States

  • Zhongshan Hospital, Fudan University

    COMPLETED

    Shanghai, Shanghai Municipality, 200032, China